Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | USP19 | O94966 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 4/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811493 | 0.83 | ALDH1A1 (0.37) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL23126624 | 0.82 | MEN1 (0.34) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL20875578 | 0.81 | PDE4A (0.40) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL23126551 | 0.81 | MEN1 (0.33) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL25149845 | 0.80 | PIM1 (0.38) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL1813916 | 0.79 | MAPT (0.42) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL25150559 | 0.78 | JAK2 (0.35) | MEN1KMT2AMAPTALDH1A1JAK2 | |
| SCHEMBL20875336 | 0.78 | MEN1 (0.33) | MEN1KMT2AMAPTALDH1A1JAK2 | |
| SCHEMBL20875562 | 0.78 | ALDH1A1 (0.37) | MEN1KMT2AMAPTALDH1A1HTT | |
| SCHEMBL1811445 | 0.77 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC (US) | 2023-04-06 | — | — | US | disclosed |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-07-14 | — | — | US | disclosed |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-07-14 | — | — | US | disclosed |
| US-11332473-B2 | Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors | NUVATION BIO INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11332473-B2 | Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors | NUVATION BIO INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11299493-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3952875-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3952877-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113939296-A | Heterocyclic compounds and their use | 诺维逊生物股份有限公司 | 2022-01-14 | — | — | CN | disclosed |
| WO-2020210375-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200325142-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-10-15 | — | — | US | disclosed |
| US-20200325142-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-10-15 | — | — | US | disclosed |
| WO-2020210380-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3694861-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299493-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, NME1 | MEN1 326/4885KMT2A 2106/4885MAPT 4445/4885 |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | WEE1, WEE2, DPYD | MEN1 2058/4885KMT2A 1842/4885MAPT 3968/4885 |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | MEN1 326/4885KMT2A 2106/4885MAPT 4445/4885 |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | MEN1 326/4885KMT2A 2106/4885MAPT 4445/4885 |
| US-20200325142-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | MEN1 326/4885KMT2A 2106/4885MAPT 4445/4885 |
| US-11332473-B2 | Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors | WEE1, WEE2, DPYD | MEN1 2058/4885KMT2A 1842/4885MAPT 3968/4885 |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | MEN1 326/4885KMT2A 2106/4885MAPT 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.